Peconic LLC is striving to achieve more advanced medical diagnosis of cancer DNA epigenomes through ultra-high-resolution epigenome monitoring, applicable for research and medical groups. The epigenome, a set of chemical compounds that modify the genome and affect gene expression, constitutes the “readers” of the DNA genome, which instructs all life processes. Monitoring the epigenome provides insight into cell type identification—a critical compo¬nent in the development of medical diagnostics—and how cells are regulated.
Application & Market Utility
Peconic LLC is developing third-generation technology to monitor thousands of biomarker “readers”. By monitoring the “readers”, environmental influences integrated in a person’s genetic blue print and affecting gene expression can be observed and tracked, providing a complete picture of health prospects. Through these means, Peconic’s ChIP-exo technology can identify cancer subtypes. Classifying a cancer based on its epigenome allows for tailored cancer therapies and improved patient outcomes, and may also translate into increased clinical success in drug discovery.
Seeking research collaboration and licensing opportunities.